In late June, CureVac published final data showing that its vaccine had demonstrated efficacy of 48% against Covid-19. "CureVac Shares Fall Premarket on Termination of Vaccine Contracts With Wacker Chemie, Celonic -- 2nd Update," at 1259 GMT Sept. 14, cited interim data from mid-June which showed the vaccine demonstrating a 47% efficacy.

 

(END) Dow Jones Newswires

September 15, 2021 04:53 ET (08:53 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Novartis.